sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
29-May-2016 21:09
US Eastern Time

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 1255.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 16-Mar-2016
Science Translational Medicine
Experimental dengue vaccine protects all recipients in virus challenge study
A clinical trial in which volunteers were infected with dengue virus six months after receiving either an experimental dengue vaccine developed by scientists from NIH or a placebo injection yielded starkly contrasting results. All 21 volunteers who received the vaccine, TV003, were protected from infection, while all 20 placebo recipients developed infection. The study underscores the importance of human challenge studies, in which volunteers are exposed to disease-causing pathogens under carefully controlled conditions.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 16-Mar-2016
Science Translational Medicine
Vermont Vaccine Testing Center study reveals effective, single-dose dengue vaccine
Results from a dengue vaccine virus challenge study show 100 percent protection in clinical trial participants tested at University of Vermont and Johns Hopkins University.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Jennifer Nachbur
jennifer.nachbur@uvm.edu
802-656-7875
University of Vermont

Public Release: 16-Mar-2016
Science Translational Medicine
Last piece of dengue vaccine puzzle found effective in small trial
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contacting the virus, the most prevalent mosquito-borne virus in the world.
NIH/National Institute of Allergy and Infectious Diseases' Intramural Research Program

Contact: Stephanie Desmon
sdesmon1@jhu.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health

Public Release: 11-Mar-2016
Nature Protocols
Differential immuno-capture biochip offers specific leukocyte counting for HIV diagnosis
Researchers from the University of Illinois at Urbana-Champaign have developed a highly sensitive biosensor based on a differential immuno-capture technology that can detect sub-populations of white blood cells. As part of a small, disposable biochip, the microfluidic biosensor can count CD4+/CD8+ T cells quickly and accurately for AIDS diagnosis in the field.

Contact: Rashid Bashir
rbashir@illinois.edu
217-333-3097
University of Illinois College of Engineering

Public Release: 10-Mar-2016
PLOS Pathogens
Patterns of brain swelling may explain susceptibility of children to cerebral malaria
Brain swelling is a strong predictor of death in children with cerebral malaria (a severe form of the disease where parasites have accumulated in brain vessels), and also in mice with experimental cerebral malaria. A high-resolution whole brain imaging analysis of swelling in ECM published on March 10 in PLOS Pathogens suggests that cerebral malaria depends on the permissive environment in a specific brain area.

Contact: Angelika Hoffmann
angelika.hoffmann@med.uni-heidelberg.de
PLOS

Public Release: 9-Mar-2016
American Journal of Human Genetics
HIV patients in Africa with a specific genetic variant have much lower rate of TB
In the first known discovery of its kind, a Case Western Reserve University School of Medicine-led team has found that HIV patients in Africa with a certain genetic variant have a 63-percent lower chance of developing tuberculosis than HIV patients without the genetic variant.

Contact: Marc Kaplan
marc.kaplan@case.edu
216-368-4692
Case Western Reserve University

Public Release: 9-Mar-2016
Journal of Psychiatric Practice
Expert outlines medical approach to treatment of traumatized refugees
What's the best approach to mental health treatment for refugees with posttraumatic symptoms? One clinic with extensive experience in managing traumatized refugees recommends a medical approach combining psychoactive medications, long-term psychotherapy, and screening and treatment for associated health issues, according to a paper in the Journal of Psychiatric Practice, published by Wolters Kluwer.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 9-Mar-2016
The Lancet HIV
Study seeks to reduce pediatric HIV infection rates in Africa
Mother-to-child transmission of the human immunodeficiency virus (HIV), which causes AIDS, is still a major problem in resource-limited, rural areas of the world where health care providers are scarce.

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center

Public Release: 9-Mar-2016
Journal of Clinical Investigation
Vanderbilt researchers identify potential antibody treatment for H7 avian flu
Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.
National Institutes of Health, US Department of Defense

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center

Public Release: 8-Mar-2016
Dengue: Stem the Tide conference 24-26 February
Dengue research conference joins forces to prevent mosquito-carried viral diseases
Umea University-led research on mosquito control and Dengue prevention was presented recently at an international conference held in Colombo, Sri Lanka on Feb. 24-26. The findings and insights from the EU-funded DengueTools research consortium could enhance preventive efforts currently underway in Brazil and other countries experiencing a Zika virus outbreak.

Contact: Daniel Harju
daniel.harju@umu.se
0046-725-522-918
Umea University

Public Release: 7-Mar-2016
Promising malaria drug created at Rutgers to undergo clinical trials
Malaria killed about 440,000 people -- mostly young children -- last year, but a new drug candidate discovered at Rutgers University may help fight the long-dreaded disease. The compound, which literally blows up malaria parasites in the blood stream, is about to undergo clinical trials, said Spencer Knapp, a chemistry professor in the Department of Chemistry and Chemical Biology at Rutgers.
National Institutes of Health, Global Health Innovation Technology Fund

Contact: Todd B. Bates
tbates@ucm.rutgers.edu
848-932-0550
Rutgers University

Public Release: 4-Mar-2016
New England Journal of Medicine
Zika linked to abnormal pregnancies, fetal death, new research finds
New research presents strong evidence that the Zika virus can indeed cause a range of abnormalities in pregnant women infected with the virus -- with the effects manifesting any time during pregnancy. Some of the abnormalities noted have not been reported in connection with the virus.

Contact: Enrique Rivero
erivero@mednet.ucla.edu
310-794-2273
University of California - Los Angeles Health Sciences

Public Release: 3-Mar-2016
Woman's Condom achieves WHO/UNFPA prequalification
The Woman's Condom, a new female condom designed to be easy to use and more acceptable to women and their partners, has been prequalified by the World Health Organization (WHO)/United Nations Population Fund (UNFPA). The approval marks a critical step forward in expanding options for female-initiated dual protection from pregnancy and sexually transmitted infections (STIs), including HIV.

Contact: Claire Hudson
media@path.org
206-302-4521
PATH

Public Release: 3-Mar-2016
Nature
Novel small-molecule antiviral compound protects monkeys from deadly Ebola virus
Rhesus monkeys were completely protected from Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings published online this week in the journal Nature.
Defense Threat Reduction Agency/The Joint Science and Technology Office for Chemical and Biological Defense

Contact: Caree Vander Linden
teresa.l.vanderlinden.civ@mail.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases

Public Release: 3-Mar-2016
Cell
Researchers unravel pathways of potent antibodies that fight HIV infection
One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates. Now a research team, led by investigators at the Duke Human Vaccine Institute and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV-infected individual and determined sequential structures that point to how they developed.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 2-Mar-2016
Quarterly Journal of Economics
Why pharmaceutical firms may prefer to invest in drugs over vaccines
When it comes to addressing disease, many industry observers and public health advocates believe that pharmaceutical companies prefer to invest in drugs rather than vaccines, as preventives are perceived to be inherently less profitable. A Harvard-Dartmouth study on preventives versus treatments recently summarized in 'VOX EU,' offers a new economic rationale for this trend -- the population risk for diseases resembles a Zipf distribution, where the demand curve for a drug is likely to support stronger revenue extraction from a drug than for a vaccine.

Contact: Amy Olson
amy.d.olson@dartmouth.edu
603-646-3274
Dartmouth College

Public Release: 2-Mar-2016
JAMA Cardiology
Study examines prevalence of rheumatic heart disease in developing country
Thomas Pilgrim, M.D., of Bern University Hospital, Bern, Switzerland, and colleagues conducted a study to determine the prevalence and incidence of clinically silent and manifest rheumatic heart disease in Eastern Nepal. The study was published online by JAMA Cardiology.

Contact: Thomas Pilgrim, M.D.
thomas.pilgrim@insel.ch
The JAMA Network Journals

Public Release: 2-Mar-2016
Nature
TSRI scientists find clues to neutralizing coronaviruses such as MERS
Scientists at the Scripps Research Institute, Dartmouth and the National Institutes of Health have solved the structure of a key protein in HKU1, a coronavirus identified in Hong Kong in 2005 and highly related to SARS and MERS. They believe their findings will guide future treatments for this family of viruses.
NIH/National Institute of Allergy and Infectious Diseases, Scripps Research Institute, Geisel School of Medicine at Dartmouth, National Institutes of Health

Contact: Madeline McCurry-Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute

Public Release: 2-Mar-2016
PLOS Biology
How to prevent 10 million deaths a year
Strategic investments to discover and develop new health tools, together with innovations in effectively delivering today's health tools and services, could avert 10 million deaths a year within just one generation, argue leading global health experts in a new PLOS Collection.

Contact: Jennifer Horsely
collections@plos.org
44-012-234-42836
PLOS

Public Release: 1-Mar-2016
JAMA Pediatrics
Children's Hospital Colorado experts publish article on the 2014 enterovirus D68 outbreak
From August to September 2014, a nationwide outbreak of enterovirus D68 (EV-D68) left resources constrained for Children's Hospital Colorado (Children's Colorado) and pediatric organizations throughout the nation. Researchers and operational experts at Children's Colorado looked at the change in hospital resources utilized during the outbreak periods and compared the data to what would have been expected during a calm respiratory season, which allowed the team to indirectly estimate the impact of the virus.
NIH/National Center for Advancing Translational Sciences

Contact: Hollon Kohtz
hollon.kohtz@childrenscolorado.org
720-777-8713
Children's Hospital Colorado

Public Release: 1-Mar-2016
Annals of Global Health
Experts assess the impact of climate change on public health
In a review published in the Annals of Global Health, doctors warn of the impending public health crisis brought on by climate change and call for action to help prepare the world for what is ahead.

Contact: Eileen Leahy
hmsmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 29-Feb-2016
Journal of Global Health
Free ambulance service halves pregnancy-related deaths in rural Ethiopia
An operational assessment of a national free ambulance services program reveals a drastic reduction in pregnancy-related deaths in rural Ethiopia, suggesting that the innovative model could offer a cost-effective way to improve maternal health outcomes across Sub-Saharan Africa. This argument is presented in an article published today in the Journal of Global Health.

Contact: Daniel Harju
anna.lawrence@umu.se
46-725-522-918
Umea University

Public Release: 29-Feb-2016
Anti-bacterial fabric holds promise for fighting superbug
An industry-academic collaborative group, involving UNIST, Yeejoo Co., Ltd., and KICET developed an anti-bacterial fabric, using a natural bacterial pigment.
Korea Institute for Advancement of Technology

Contact: JooHyeon Heo
joohyeonheo@unist.ac.kr
82-522-171-223
Ulsan National Institute of Science and Technology(UNIST)

Public Release: 29-Feb-2016
PLOS Neglected Tropical Diseases
Risk of catching Ebola from survivor 'very low'
New research finds the risk of catching Ebola from a survivor to be 'very low.' Researchers set out to discover how long the Ebola virus persists in different human body fluids -- including blood, urine, semen, sweat, breast milk, feces, and vaginal fluids. While other health complications have been widely reported, the team did not find any evidence that the virus can reactivate to the point it becomes infectious for others by non-sexual contact.
National Institute for Health Research Health Protection Research Unit on Emergency Preparedness and Response

Contact: Lisa Horton
press@uea.ac.uk
44-016-035-93496
University of East Anglia

Public Release: 29-Feb-2016
Vaccine
New vaccine could save thousands of lives
Work led by University of Exeter experts could help to protect thousands of people from an often fatal disease found in most tropical regions.
Fondazione CARIPLO

Contact: Kerra Maddern
k.l.maddern@exeter.ac.uk
44-139-272-2062
University of Exeter

Showing releases 151-175 out of 1255.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>